O	O	0	8	Negative	Negative	B-NP	JJ	O	2	NMOD	O
O	O	9	19	regulation	regulation	I-NP	NN	O	13	NMOD	O
O	O	20	22	of	of	B-PP	IN	O	2	NMOD	O
O	O	23	28	human	human	B-NP	JJ	O	9	NMOD	O
O	O	29	45	immunodeficiency	immunodeficiency	I-NP	NN	O	9	NMOD	O
O	O	46	51	virus	virus	I-NP	NN	O	9	NMOD	O
O	O	52	56	type	type	I-NP	NN	O	9	NMOD	O
O	O	57	58	1	1	I-NP	CD	O	9	NMOD	O
O	O	59	69	expression	expression	I-NP	NN	O	3	PMOD	O
O	O	70	72	in	in	B-PP	IN	O	9	NMOD	O
O	O	73	82	monocytes	monocyte	B-NP	NNS	B-cell_type	10	PMOD	B-cell_type
O	O	82	83	:	:	O	:	O	2	P	O
O	O	84	88	role	role	B-NP	NN	O	0	ROOT	O
O	O	89	91	of	of	B-PP	IN	O	13	NMOD	O
O	O	92	95	the	the	B-NP	DT	O	18	NMOD	O
T1	B-Protein	96	98	65	65	I-NP	CD	B-protein	18	NMOD	B-protein
T1	I-Protein	98	99	-	-	I-NP	HYPH	I-protein	18	NMOD	I-protein
T1	I-Protein	99	102	kDa	kDa	I-NP	NN	I-protein	22	AMOD	I-protein
O	O	103	107	plus	plus	O	CC	O	22	AMOD	O
T2	B-Protein	108	110	50	50	B-NP	CD	B-protein	22	AMOD	B-protein
T2	I-Protein	110	111	-	-	I-NP	HYPH	I-protein	22	AMOD	I-protein
T2	I-Protein	111	114	kDa	kDa	I-NP	NN	I-protein	27	NMOD	I-protein
T7	B-Entity	115	117	NF	NF	I-NP	NN	I-protein	27	NMOD	I-protein
T7	I-Entity	117	118	-	-	B-NP	HYPH	I-protein	27	NMOD	I-protein
T7	I-Entity	118	123	kappa	kappa	I-NP	NN	I-protein	27	NMOD	I-protein
T7	I-Entity	124	125	B	B	I-NP	NN	I-protein	27	NMOD	I-protein
T7	I-Entity	126	131	dimer	dimer	I-NP	NN	I-protein	14	PMOD	I-protein
O	O	131	132	.	.	O	.	O	13	P	O

O	O	134	142	Although	Although	B-SBAR	IN	O	28	VMOD	O
O	O	143	152	monocytic	monocytic	B-NP	JJ	B-cell_type	3	NMOD	B-cell_type
O	O	153	158	cells	cell	I-NP	NNS	I-cell_type	4	SUB	I-cell_type
O	O	159	162	can	can	B-VP	MD	O	1	SBAR	O
O	O	163	170	provide	provide	I-VP	VB	O	4	VC	O
O	O	171	172	a	a	B-NP	DT	O	7	NMOD	O
O	O	173	182	reservoir	reservoir	I-NP	NN	O	5	OBJ	O
O	O	183	186	for	for	B-PP	IN	O	7	NMOD	O
O	O	187	192	viral	viral	B-NP	JJ	O	10	NMOD	O
O	O	193	203	production	production	I-NP	NN	O	8	PMOD	O
O	O	204	206	in	in	B-ADVP	FW	O	10	NMOD	O
O	O	207	211	vivo	vivo	I-ADVP	FW	O	11	AMOD	O
O	O	211	212	,	,	O	,	O	28	P	O
O	O	213	218	their	their	B-NP	PRP$	O	15	NMOD	O
O	O	219	229	regulation	regulation	I-NP	NN	O	28	SUB	O
O	O	230	232	of	of	B-PP	IN	O	15	NMOD	O
O	O	233	238	human	human	B-NP	JJ	O	20	NMOD	O
O	O	239	255	immunodeficiency	immunodeficiency	I-NP	NN	O	20	NMOD	O
O	O	256	261	virus	virus	I-NP	NN	O	20	NMOD	O
O	O	262	266	type	type	I-NP	NN	O	27	NMOD	O
O	O	267	268	1	1	I-NP	CD	O	20	NMOD	O
O	O	269	270	(	(	O	(	O	26	DEP	O
O	O	270	273	HIV	HIV	O	NN	O	26	DEP	O
O	O	273	274	-	-	O	HYPH	O	25	P	O
O	O	274	275	1	1	O	CD	O	26	DEP	O
O	O	275	276	)	)	O	)	O	20	NMOD	O
O	O	277	290	transcription	transcription	B-NP	NN	O	16	PMOD	O
O	O	291	294	can	can	B-VP	MD	O	0	ROOT	O
O	O	295	297	be	be	I-VP	VB	O	28	VC	O
O	O	298	304	either	either	O	CC	O	36	AMOD	O
O	O	305	311	latent	latent	B-ADJP	JJ	O	36	AMOD	O
O	O	311	312	,	,	O	,	O	36	P	O
O	O	313	323	restricted	restricted	B-ADJP	JJ	O	36	AMOD	O
O	O	323	324	,	,	O	,	O	36	P	O
O	O	325	327	or	or	O	CC	O	36	AMOD	O
O	O	328	338	productive	productive	B-ADJP	JJ	O	29	PRD	O
O	O	338	339	.	.	O	.	O	28	P	O

O	O	340	345	These	These	B-NP	DT	O	2	NMOD	O
O	O	346	357	differences	difference	I-NP	NNS	O	6	SUB	O
O	O	358	360	in	in	B-PP	IN	O	2	NMOD	O
O	O	361	365	gene	gene	B-NP	NN	O	5	NMOD	O
O	O	366	376	expression	expression	I-NP	NN	O	3	PMOD	O
O	O	377	381	have	have	B-VP	VBP	O	0	ROOT	O
O	O	382	385	not	not	I-VP	RB	O	6	VMOD	O
O	O	386	390	been	be	I-VP	VBN	O	6	VC	O
O	O	391	402	molecularly	molecularly	B-ADJP	RB	O	10	AMOD	O
O	O	403	410	defined	define	I-ADJP	VBN	O	8	PRD	O
O	O	410	411	.	.	O	.	O	6	P	O

O	O	412	414	In	In	B-PP	IN	O	12	VMOD	O
O	O	415	418	THP	THP	B-NP	NN	B-cell_line	5	NMOD	B-cell_line
O	O	418	419	-	-	B-NP	HYPH	I-cell_line	5	NMOD	I-cell_line
O	O	419	420	1	1	I-NP	CD	I-cell_line	5	NMOD	I-cell_line
O	O	421	426	cells	cell	I-NP	NNS	I-cell_line	1	PMOD	I-cell_line
O	O	427	431	with	with	B-PP	IN	O	5	NMOD	O
O	O	432	442	restricted	restricted	B-NP	JJ	O	9	NMOD	O
O	O	443	446	HIV	HIV	I-NP	NN	O	9	NMOD	O
O	O	447	457	expression	expression	I-NP	NN	O	6	PMOD	O
O	O	457	458	,	,	O	,	O	12	P	O
O	O	459	464	there	there	B-NP	EX	O	12	SUB	O
O	O	465	467	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	468	470	an	an	B-NP	DT	O	14	NMOD	O
O	O	471	478	absence	absence	I-NP	NN	O	12	PRD	O
O	O	479	481	of	of	B-PP	IN	O	14	NMOD	O
T8,T9	B-Entity,B-Entity	482	485	DNA	DNA	B-NP	NN	O	21	NMOD	O
T8	I-Entity	485	486	-	-	B-NP	HYPH	O	21	NMOD	O
T8	I-Entity	486	493	protein	protein	I-NP	NN	B-protein	21	NMOD	B-protein
T8	I-Entity	494	501	binding	binding	I-NP	NN	I-protein	21	NMOD	I-protein
T8	I-Entity	502	509	complex	complex	I-NP	NN	I-protein	21	NMOD	I-protein
O	O	510	519	formation	formation	I-NP	NN	O	15	PMOD	O
O	O	520	524	with	with	B-PP	IN	O	21	NMOD	O
O	O	525	528	the	the	B-NP	DT	O	27	NMOD	O
T10	B-Entity	529	532	HIV	HIV	I-NP	NN	B-DNA	27	NMOD	B-DNA
T10	I-Entity	532	533	-	-	B-NP	HYPH	I-DNA	27	P	I-DNA
T10	I-Entity	533	534	1	1	I-NP	CD	I-DNA	27	NMOD	I-DNA
T10	I-Entity	535	543	promoter	promoter	I-NP	NN	I-DNA	29	NMOD	I-DNA
T10	I-Entity	543	544	-	-	B-NP	HYPH	O	29	P	O
T10	I-Entity	544	552	enhancer	enhancer	I-NP	NN	B-DNA	22	PMOD	B-DNA
O	O	553	563	associated	associate	B-VP	VBN	O	29	NMOD	O
O	O	564	568	with	with	B-PP	IN	O	30	VMOD	O
O	O	569	577	markedly	markedly	B-NP	RB	O	36	NMOD	O
O	O	578	582	less	less	I-NP	JJR	O	32	AMOD	O
O	O	583	588	viral	viral	I-NP	JJ	B-RNA	36	NMOD	B-RNA
O	O	589	592	RNA	RNA	I-NP	NN	I-RNA	36	NMOD	I-RNA
O	O	593	603	production	production	I-NP	NN	O	31	PMOD	O
O	O	603	604	.	.	O	.	O	12	P	O

O	O	605	609	This	This	B-NP	DT	O	2	NMOD	O
O	O	610	617	absence	absence	I-NP	NN	O	5	SUB	O
O	O	618	620	of	of	B-PP	IN	O	2	NMOD	O
O	O	621	628	binding	binding	B-NP	NN	O	3	PMOD	O
O	O	629	632	was	be	B-VP	VBD	O	34	VMOD	O
O	O	633	642	localized	localized	B-ADJP	JJ	O	5	VC	O
O	O	643	645	to	to	B-PP	TO	O	6	VMOD	O
O	O	646	649	the	the	B-NP	DT	O	13	NMOD	O
T11,T12	B-Entity,B-Entity	650	652	NF	NF	I-NP	NN	B-DNA	13	NMOD	B-DNA
T11,T12	I-Entity,I-Entity	652	653	-	-	B-NP	HYPH	I-DNA	13	NMOD	I-DNA
T11,T12	I-Entity,I-Entity	653	658	kappa	kappa	I-NP	NN	I-DNA	13	NMOD	I-DNA
T11,T12	I-Entity,I-Entity	659	660	B	B	I-NP	NN	I-DNA	13	NMOD	I-DNA
T11	I-Entity	661	667	region	region	I-NP	NN	I-DNA	7	PMOD	I-DNA
O	O	668	670	of	of	B-PP	IN	O	13	NMOD	O
O	O	671	674	the	the	B-NP	DT	O	19	NMOD	O
T13	B-Entity	675	678	HIV	HIV	I-NP	NN	B-DNA	19	NMOD	B-DNA
T13	I-Entity	678	679	-	-	B-NP	HYPH	I-DNA	19	NMOD	I-DNA
T13	I-Entity	679	680	1	1	I-NP	CD	I-DNA	19	NMOD	I-DNA
T13	I-Entity	681	689	enhancer	enhancer	I-NP	NN	I-DNA	14	PMOD	I-DNA
O	O	689	690	;	;	O	:	O	34	P	O
O	O	691	694	the	the	B-NP	DT	O	24	NMOD	O
T3	B-Protein	695	697	65	65	I-NP	CD	B-protein	24	NMOD	B-protein
T3	I-Protein	697	698	-	-	I-NP	HYPH	I-protein	24	NMOD	I-protein
T3	I-Protein	698	701	kDa	kDa	I-NP	NN	I-protein	28	AMOD	I-protein
O	O	702	706	plus	plus	O	CC	O	28	AMOD	O
T4	B-Protein	707	709	50	50	B-NP	CD	B-protein	28	AMOD	B-protein
T4	I-Protein	709	710	-	-	I-NP	HYPH	I-protein	28	AMOD	I-protein
T4	I-Protein	710	713	kDa	kDa	I-NP	NN	I-protein	33	NMOD	I-protein
T14	B-Entity	714	716	NF	NF	I-NP	NN	I-protein	33	NMOD	I-protein
T14	I-Entity	716	717	-	-	B-NP	HYPH	I-protein	33	NMOD	I-protein
T14	I-Entity	717	722	kappa	kappa	I-NP	NN	I-protein	33	NMOD	I-protein
T14	I-Entity	723	724	B	B	I-NP	NN	I-protein	33	NMOD	I-protein
T14	I-Entity	725	736	heterodimer	heterodimer	I-NP	NN	I-protein	34	SUB	I-protein
O	O	737	740	was	be	B-VP	VBD	O	0	ROOT	O
O	O	741	755	preferentially	preferentially	B-ADJP	RB	O	36	AMOD	O
O	O	756	760	lost	lose	I-ADJP	VBN	O	34	PRD	O
O	O	760	761	.	.	O	.	O	34	P	O

O	O	762	768	Adding	Add	B-VP	VBG	O	16	SUB	O
O	O	769	777	purified	purify	B-NP	VBN	O	7	NMOD	O
O	O	778	780	NF	NF	I-NP	NN	B-protein	7	NMOD	B-protein
O	O	780	781	-	-	B-NP	HYPH	I-protein	7	NMOD	I-protein
O	O	781	786	kappa	kappa	I-NP	NN	I-protein	7	NMOD	I-protein
O	O	787	788	B	B	I-NP	NN	I-protein	7	NMOD	I-protein
O	O	789	796	protein	protein	I-NP	NN	I-protein	1	OBJ	I-protein
O	O	797	799	to	to	B-PP	TO	O	1	VMOD	O
O	O	800	807	nuclear	nuclear	B-NP	JJ	O	10	NMOD	O
O	O	808	816	extracts	extract	I-NP	NNS	O	8	PMOD	O
O	O	817	821	from	from	B-PP	IN	O	10	NMOD	O
O	O	822	827	cells	cell	B-NP	NNS	O	11	PMOD	O
O	O	828	832	with	with	B-PP	IN	O	12	NMOD	O
O	O	833	843	restricted	restricted	B-NP	JJ	O	15	NMOD	O
O	O	844	854	expression	expression	I-NP	NN	O	13	PMOD	O
O	O	855	864	overcomes	overcome	B-VP	VBZ	O	0	ROOT	O
O	O	865	869	this	this	B-NP	DT	O	18	NMOD	O
O	O	870	874	lack	lack	I-NP	NN	O	16	OBJ	O
O	O	875	877	of	of	B-PP	IN	O	18	NMOD	O
O	O	878	885	binding	binding	B-NP	NN	O	19	PMOD	O
O	O	885	886	.	.	O	.	O	16	P	O

O	O	887	889	In	In	B-PP	IN	O	12	VMOD	O
O	O	890	898	addition	addition	B-NP	NN	O	1	PMOD	O
O	O	898	899	,	,	O	,	O	12	P	O
O	O	900	909	treatment	treatment	B-NP	NN	O	12	SUB	O
O	O	910	912	of	of	B-PP	IN	O	4	NMOD	O
O	O	913	918	these	these	B-NP	DT	O	8	NMOD	O
O	O	919	926	nuclear	nuclear	I-NP	JJ	O	8	NMOD	O
O	O	927	935	extracts	extract	I-NP	NNS	O	5	PMOD	O
O	O	936	940	with	with	B-PP	IN	O	4	NMOD	O
O	O	941	947	sodium	sodium	B-NP	NN	O	11	NMOD	O
O	O	948	960	deoxycholate	deoxycholate	I-NP	NN	O	9	PMOD	O
O	O	961	969	restored	restore	B-VP	VBD	O	0	ROOT	O
O	O	970	975	their	their	B-NP	PRP$	O	14	NMOD	O
O	O	976	983	ability	ability	I-NP	NN	O	12	OBJ	O
O	O	984	986	to	to	B-VP	TO	O	16	VMOD	O
O	O	987	991	form	form	I-VP	VB	O	14	NMOD	O
O	O	992	995	the	the	B-NP	DT	O	18	NMOD	O
T15	B-Entity	996	1007	heterodimer	heterodimer	I-NP	NN	B-protein	16	OBJ	B-protein
O	O	1007	1008	,	,	O	,	O	12	P	O
O	O	1009	1019	suggesting	suggest	B-VP	VBG	O	12	VMOD	O
O	O	1020	1023	the	the	B-NP	DT	O	22	NMOD	O
O	O	1024	1032	presence	presence	I-NP	NN	O	20	OBJ	O
O	O	1033	1035	of	of	B-PP	IN	O	22	NMOD	O
O	O	1036	1038	an	an	B-NP	DT	O	25	NMOD	O
O	O	1039	1048	inhibitor	inhibitor	I-NP	NN	O	23	PMOD	O
O	O	1049	1051	of	of	B-PP	IN	O	25	NMOD	O
T16	B-Entity	1052	1054	NF	NF	B-NP	NN	B-protein	31	NMOD	B-protein
T16	I-Entity	1054	1055	-	-	B-NP	HYPH	I-protein	31	NMOD	I-protein
T16	I-Entity	1055	1060	kappa	kappa	I-NP	NN	I-protein	31	NMOD	I-protein
T16	I-Entity	1061	1062	B	B	I-NP	NN	I-protein	31	NMOD	I-protein
O	O	1063	1071	activity	activity	I-NP	NN	O	26	PMOD	O
O	O	1071	1072	.	.	O	.	O	12	P	O

O	O	1073	1084	Furthermore	Furthermore	B-ADVP	RB	O	0	ROOT	O
O	O	1084	1085	,	,	O	,	O	1	P	O
O	O	1086	1095	treatment	treatment	B-NP	NN	O	2	ROOT	O
O	O	1096	1098	of	of	B-PP	IN	O	3	NMOD	O
O	O	1099	1106	nuclear	nuclear	B-NP	JJ	O	6	NMOD	O
O	O	1107	1115	extracts	extract	I-NP	NNS	O	4	PMOD	O
O	O	1116	1120	from	from	B-PP	IN	O	6	NMOD	O
O	O	1121	1126	these	these	B-NP	DT	O	9	NMOD	O
O	O	1127	1132	cells	cell	I-NP	NNS	O	7	PMOD	O
O	O	1133	1137	that	that	B-NP	WDT	O	6	NMOD	O
O	O	1138	1141	had	have	B-VP	VBD	O	10	SBAR	O
O	O	1142	1152	restricted	restrict	I-VP	VBN	O	13	NMOD	O
O	O	1153	1163	expression	expression	B-NP	NN	O	11	OBJ	O
O	O	1164	1168	with	with	B-PP	IN	O	11	VMOD	O
O	O	1169	1187	lipopolysaccharide	lipopolysaccharide	B-NP	NN	O	16	SUB	O
O	O	1188	1197	increased	increase	B-VP	VBD	O	14	SBAR	O
O	O	1198	1203	viral	viral	B-NP	JJ	O	18	NMOD	O
O	O	1204	1214	production	production	I-NP	NN	O	24	NMOD	O
O	O	1215	1218	and	and	I-NP	CC	O	24	NMOD	O
T17	B-Entity	1219	1221	NF	NF	I-NP	NN	B-protein	24	NMOD	B-protein
T17	I-Entity	1221	1222	-	-	B-NP	HYPH	I-protein	24	NMOD	I-protein
T17	I-Entity	1222	1227	kappa	kappa	I-NP	NN	I-protein	24	NMOD	I-protein
T17	I-Entity	1228	1229	B	B	I-NP	NN	I-protein	24	NMOD	I-protein
O	O	1230	1238	activity	activity	I-NP	NN	O	16	OBJ	O
O	O	1238	1239	.	.	O	.	O	3	P	O

O	O	1240	1249	Antiserum	Antiserum	B-NP	NN	O	18	NMOD	O
O	O	1250	1258	specific	specific	B-ADJP	JJ	O	1	NMOD	O
O	O	1259	1262	for	for	B-PP	IN	O	2	AMOD	O
T18	B-Entity	1263	1265	NF	NF	B-NP	NN	B-protein	9	NMOD	B-protein
T18	I-Entity	1265	1266	-	-	B-NP	HYPH	I-protein	9	NMOD	I-protein
T18	I-Entity	1266	1271	kappa	kappa	I-NP	NN	I-protein	9	NMOD	I-protein
T18	I-Entity	1272	1273	B	B	I-NP	NN	I-protein	9	NMOD	I-protein
O	O	1274	1281	binding	binding	I-NP	NN	I-protein	9	NMOD	I-protein
O	O	1282	1290	proteins	protein	I-NP	NNS	I-protein	3	PMOD	I-protein
O	O	1290	1291	,	,	O	,	O	18	P	O
O	O	1292	1295	but	but	O	CC	O	18	NMOD	O
O	O	1296	1299	not	not	O	RB	O	11	DEP	O
O	O	1300	1301	c	c	B-NP	NN	B-protein	15	NMOD	B-protein
O	O	1301	1302	-	-	B-NP	HYPH	I-protein	15	NMOD	I-protein
O	O	1302	1305	rel	rel	I-NP	NN	I-protein	18	NMOD	I-protein
O	O	1305	1306	-	-	B-NP	HYPH	O	18	NMOD	O
O	O	1306	1314	specific	specific	I-NP	JJ	O	18	NMOD	O
O	O	1315	1324	antiserum	antiserum	I-NP	NN	O	20	SUB	O
O	O	1324	1325	,	,	O	,	O	18	P	O
O	O	1326	1335	disrupted	disrupt	B-VP	VBD	O	0	ROOT	O
T19	B-Entity	1336	1347	heterodimer	heterodimer	B-NP	NN	B-protein	23	NMOD	B-protein
T19	I-Entity	1348	1355	complex	complex	I-NP	NN	I-protein	23	NMOD	I-protein
O	O	1356	1365	formation	formation	I-NP	NN	O	20	OBJ	O
O	O	1365	1366	.	.	O	.	O	20	P	O

O	O	1367	1371	Thus	Thus	B-ADVP	RB	O	11	VMOD	O
O	O	1371	1372	,	,	O	,	O	11	P	O
O	O	1373	1377	both	both	O	CC	O	10	NMOD	O
T20	B-Entity	1378	1380	NF	NF	B-NP	NN	B-protein	7	NMOD	B-protein
T20	I-Entity	1380	1381	-	-	O	HYPH	I-protein	7	NMOD	I-protein
T20	I-Entity	1381	1386	kappa	kappa	B-NP	NN	I-protein	7	NMOD	I-protein
T20	I-Entity	1387	1388	B	B	I-NP	NN	I-protein	10	NMOD	I-protein
T20	I-Entity	1388	1389	-	-	B-VP	HYPH	O	10	NMOD	O
T20	I-Entity	1389	1396	binding	bind	B-NP	VBG	O	10	NMOD	O
T20	I-Entity	1397	1406	complexes	complex	I-NP	NNS	O	11	SUB	O
O	O	1407	1410	are	be	B-VP	VBP	O	0	ROOT	O
O	O	1411	1417	needed	need	I-VP	VBN	O	11	VC	O
O	O	1418	1421	for	for	B-PP	IN	O	12	VMOD	O
O	O	1422	1429	optimal	optimal	B-NP	JJ	O	16	NMOD	O
O	O	1430	1435	viral	viral	I-NP	JJ	O	16	NMOD	O
O	O	1436	1449	transcription	transcription	I-NP	NN	O	13	PMOD	O
O	O	1449	1450	.	.	O	.	O	11	P	O

O	O	1451	1458	Binding	Binding	B-NP	NN	O	18	SUB	O
O	O	1459	1461	of	of	B-PP	IN	O	1	NMOD	O
O	O	1462	1465	the	the	B-NP	DT	O	6	NMOD	O
T5	B-Protein	1466	1468	65	65	I-NP	CD	B-protein	6	NMOD	B-protein
T5	I-Protein	1468	1469	-	-	I-NP	HYPH	I-protein	6	NMOD	I-protein
T5	I-Protein	1469	1472	kDa	kDa	I-NP	NN	I-protein	11	NMOD	I-protein
O	O	1473	1477	plus	plus	O	CC	O	11	NMOD	O
T6	B-Protein	1478	1480	50	50	B-NP	CD	B-protein	11	NMOD	B-protein
T6	I-Protein	1480	1481	-	-	I-NP	HYPH	I-protein	11	NMOD	I-protein
T6	I-Protein	1481	1484	kDa	kDa	I-NP	NN	I-protein	11	NMOD	I-protein
T21	B-Entity	1485	1496	heterodimer	heterodimer	I-NP	NN	I-protein	2	PMOD	I-protein
O	O	1497	1499	to	to	B-PP	TO	O	1	NMOD	O
O	O	1500	1503	the	the	B-NP	DT	O	17	NMOD	O
T22	B-Entity	1504	1507	HIV	HIV	I-NP	NN	B-DNA	17	NMOD	B-DNA
T22	I-Entity	1507	1508	-	-	B-NP	HYPH	I-DNA	17	NMOD	I-DNA
T22	I-Entity	1508	1509	1	1	I-NP	CD	I-DNA	17	NMOD	I-DNA
T22	I-Entity	1510	1518	enhancer	enhancer	I-NP	NN	I-DNA	12	PMOD	I-DNA
O	O	1519	1522	can	can	B-VP	MD	O	0	ROOT	O
O	O	1523	1525	be	be	I-VP	VB	O	18	VC	O
O	O	1526	1536	negatively	negatively	I-VP	RB	O	19	VMOD	O
O	O	1537	1546	regulated	regulate	I-VP	VBN	O	19	VC	O
O	O	1547	1549	in	in	B-PP	IN	O	21	VMOD	O
O	O	1550	1559	monocytes	monocyte	B-NP	NNS	B-cell_type	22	PMOD	B-cell_type
O	O	1559	1560	,	,	O	,	O	21	P	O
O	O	1561	1570	providing	provide	B-VP	VBG	O	21	VMOD	O
O	O	1571	1574	one	one	B-NP	CD	O	27	NMOD	O
O	O	1575	1584	mechanism	mechanism	I-NP	NN	O	25	OBJ	O
O	O	1585	1596	restricting	restrict	B-VP	VBG	O	27	NMOD	O
T23	B-Entity	1597	1600	HIV	HIV	B-NP	NN	B-DNA	32	NMOD	B-DNA
T23	I-Entity	1600	1601	-	-	I-NP	HYPH	I-DNA	32	NMOD	I-DNA
T23	I-Entity	1601	1602	1	1	I-NP	CD	I-DNA	32	NMOD	I-DNA
T23	I-Entity	1603	1607	gene	gene	I-NP	NN	I-DNA	33	NMOD	I-DNA
O	O	1608	1618	expression	expression	I-NP	NN	O	28	OBJ	O
O	O	1618	1619	.	.	O	.	O	18	P	O
